Citius Pharmaceuticals announces $5 million direct offering for LYMPHIR launch and development
Updated
Updated · PR Newswire · Apr 24
Citius Pharmaceuticals announces $5 million direct offering for LYMPHIR launch and development
9 articles · Updated · PR Newswire · Apr 24
The company will issue 5,076,143 shares at $0.985 each and unregistered warrants in a concurrent private placement, with H.C. Wainwright & Co. as exclusive placement agent.
Proceeds will support the commercial launch of LYMPHIR, milestone and regulatory payments, product development, and general corporate purposes. The offering is expected to close around April 24, 2026, pending customary conditions.
Citius launched LYMPHIR in December 2025 for relapsed or refractory CTCL and continues to advance late-stage candidates Mino-Lok and Halo-Lido, engaging with the FDA on next steps for both programs.
Beyond its cancer drug, can Citius's promising pipeline ever reach the market with such limited funding?
Why would investors pay a premium for Citius stock when the company is on the brink of insolvency?
With only weeks of cash left, is this $5 million raise a lifeline or just delaying the inevitable for Citius?
Is Citius's latest financing a strategic move for growth or a desperate measure to keep the lights on?
Can a breakthrough cancer drug alone save a company battling immense costs and a ticking financial clock?